Research programme: histone deacetylase inhibitors - EOS/Karus Therapeutics

Drug Profile

Research programme: histone deacetylase inhibitors - EOS/Karus Therapeutics

Alternative Names: 4800 research programme - EOS; E-162; HDAC inibitors - EOS/Karus Therapeutics; KA001; KAR-2261; Spiruchostatin analogues - EOS/Karus Therapeutics

Latest Information Update: 28 Aug 2013

Price : $50

At a glance

  • Originator Karus Therapeutics
  • Developer EOS S.p.A.; Karus Therapeutics
  • Class Depsipeptides
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 28 Aug 2013 Discontinued - Preclinical for Cancer in Italy (unspecified route)
  • 28 Aug 2013 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
  • 19 Jan 2010 This research programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top